3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
23
Genitourinary
1
Conditions
Renal Insufficiency
1
Multiple Myeloma
1
Kidney Failure, Chronic
1
Interventions
pembrolizumab
65
Nivolumab
58
Magnetic Resonance Spectroscopy
53
enzalutamide
39
Abiraterone Acetate
37
Radiosurgery
36
Gemcitabine
35
Specimen Handling
32
Radiotherapy
32
Ipilimumab
32
Androgen Antagonists
32
Prednisone
31
apalutamide
28
Cisplatin
28
Docetaxel
27
Leuprolide
26
atezolizumab
25
Carboplatin
25
durvalumab
23
cabozantinib
23
darolutamide
20
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
19
olaparib
18
Goserelin
17
Radiation
16
Gonadotropin-Releasing Hormone
16
Biopsy
16
gallium 68 PSMA-11
15
Pluvicto
15
avelumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
belantamab mafodotin
×
Genitourinary
×
Clear all
NCT04398745
2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1
Active not recruiting
36 enrolled